Sonoma Pharmaceuticals, Inc. (SNOA) Stock

Sonoma Pharmaceuticals, Inc. specializes in the development and manufacturing of stabilized hypochlorous acid (HOCl) products designed for diverse healthcare applications. Headquartered in Woodstock, Georgia, the company operates globally, serving markets across the United States, Latin America, Europe, and beyond. Sonoma Pharmaceuticals' product portfolio includes Epicyn, an antimicrobial facial cleanser, and Levicyn, a prescription HOCl-based product that addresses dermatological conditions by alleviating symptoms such as burning, itching, and pain.

The company also offers Celacyn gel, another HOCl-based topical prescription product focused on promoting efficient wound healing and managing both new and old scars. Additional products like SebuDerm and Acuicyn cater to specific dermatological needs, providing relief from conditions such as seborrhea, seborrheic dermatitis, itch, inflammation, and other related symptoms. Sonoma Pharmaceuticals further supports veterinary care with MicrocynAH, an HOCl-based solution for treating hot spots, scratches, and other skin irritations in animals.

Originally founded as Oculus Innovative Sciences, Inc. and rebranded in December 2016, Sonoma Pharmaceuticals continues to expand its product line to include solutions like Microcyn for wound healing, MucoClyns for emergency use on mucous membranes, and Gramaderm for acne treatment. The company's commitment to leeveraging HOCl technology underscores its mission to deliver effective and innovative healthcare solutions worldwide, addressing a wide range of medical and veterinary needs.